Comparison of extraction methods for per- and polyfluoroalkyl substances (PFAS) in human serum and placenta samples-insights into extractable organic fluorine (EOF).


Journal

Analytical and bioanalytical chemistry
ISSN: 1618-2650
Titre abrégé: Anal Bioanal Chem
Pays: Germany
ID NLM: 101134327

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 31 08 2020
accepted: 02 11 2020
revised: 25 10 2020
pubmed: 21 11 2020
medline: 29 6 2021
entrez: 20 11 2020
Statut: ppublish

Résumé

Since the detection of per- and polyfluoroalkyl substances (PFAS) in humans and different environmental media in the last two decades, this substance group has attracted a lot of attention as well as increasing concerns. The fluorine mass balance approach, by comparing the levels of targeted PFAS after conversion to fluorine equivalents with those of extractable organic fluorine (EOF), showed the presence of unidentified organofluorine in different environmental samples. Out of the thousands of PFAS in existence, only a very small fraction is included in routine analysis. In recent years, liquid chromatography coupled with tandem-mass spectrometry (LC-MS/MS) has demonstrated the ability to analytically cover a wide spectrum of PFAS. In contrast, conventional extraction methods developed 10 to 15 years ago were only evaluated for a limited number of PFAS. The aim of the present study was to evaluate the advantages and disadvantages of three different extraction methods, adapted from the literatures without further optimization (ion-pair liquid-liquid extraction, solid-phase extraction (SPE), using hydrophilic-lipophilic (HLB) or weak anion exchange (WAX) sorbents), for human biomonitoring of 61 PFAS in serum and placental tissue samples. In addition, levels of EOF were compared among these extraction methods via spiked samples. Results showed that performance, in terms of recovery, differed between the extraction methods for different PFAS; different extraction methods resulted in different EOF concentrations indicating that the choice of extraction method is important for target PFAS and EOF analysis. Results of maternal serum samples, analyzed in two different laboratories using two different extraction methods, showed an accordance of 107.6% (± 21.3); the detected perfluoroalkyl acids (PFAAs) in maternal and cord serum samples were in the range of 0.076 to 2.9 ng/mL.Graphical abstract.

Identifiants

pubmed: 33215313
doi: 10.1007/s00216-020-03041-5
pii: 10.1007/s00216-020-03041-5
pmc: PMC7809006
doi:

Substances chimiques

Fluorocarbons 0
Fluorine 284SYP0193

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

865-876

Subventions

Organisme : Stiftelsen för Kunskaps- och Kompetensutveckling
ID : 20160019
Organisme : Svenska Forskningsrådet Formas
ID : 2016-01158

Références

Environ Int. 2020 Feb;135:105419
pubmed: 31874352
Talanta. 2013 Oct 15;115:104-22
pubmed: 24054567
EFSA J. 2020 Sep 17;18(9):e06223
pubmed: 32994824
Chemosphere. 2013 May;91(8):1099-106
pubmed: 23399300
Environ Sci Technol. 2013 Sep 17;47(18):10619-27
pubmed: 23980546
Crit Rev Toxicol. 2004 Jul-Aug;34(4):351-84
pubmed: 15328768
Int J Hyg Environ Health. 2017 Apr;220(2 Pt B):455-460
pubmed: 28073630
Environ Sci Technol. 2001 Feb 15;35(4):766-70
pubmed: 11349290
Int J Hyg Environ Health. 2009 May;212(3):239-70
pubmed: 18565792
Int J Hyg Environ Health. 2008 Jul;211(3-4):440-6
pubmed: 17870667
Environ Int. 2015 Apr;77:148-59
pubmed: 25728452
Environ Sci Technol. 2013 Apr 16;47(8):3875-82
pubmed: 23484930
Toxicol Sci. 2007 Oct;99(2):366-94
pubmed: 17519394
Int J Hyg Environ Health. 2012 Feb;215(2):216-9
pubmed: 21937271
J Chromatogr A. 2005 Nov 4;1093(1-2):89-97
pubmed: 16233874
Talanta. 2016 Apr 1;150:169-76
pubmed: 26838396
Environ Sci Technol. 2020 Oct 20;54(20):12850-12859
pubmed: 32915549
Anal Chim Acta. 2008 Jul 7;619(2):221-30
pubmed: 18558116
Int J Environ Res Public Health. 2018 May 14;15(5):
pubmed: 29758015
Environ Sci Process Impacts. 2020 Apr 29;22(4):1071-1083
pubmed: 32182307
Environ Sci Technol. 2004 Sep 1;38(17):4489-95
pubmed: 15461154
Integr Environ Assess Manag. 2011 Oct;7(4):513-41
pubmed: 21793199
Environ Int. 2019 Jun;127:671-684
pubmed: 30991223
Environ Health. 2013 Apr 19;12(1):35
pubmed: 23597293
J Immunotoxicol. 2017 Dec;14(1):188-195
pubmed: 28805477
Chemosphere. 2019 Apr;220:493-500
pubmed: 30594801
Environ Sci Technol. 2013 Apr 16;47(8):3865-74
pubmed: 23484973
J Chromatogr A. 2009 Jan 16;1216(3):394-400
pubmed: 19026417
J Hazard Mater. 2016 Apr 15;307:55-63
pubmed: 26775106
Environ Sci Technol. 2006 Jan 1;40(1):32-44
pubmed: 16433330
J Chromatogr A. 2007 Mar 2;1143(1-2):98-104
pubmed: 17229428
Environ Sci Technol. 2004 Jul 1;38(13):3698-704
pubmed: 15296323

Auteurs

Andreas-Marius Kaiser (AM)

Environment Agency Austria, Spittelauer Lände 5, 1090, Vienna, Austria. Andreas.Kaiser@umweltbundesamt.at.
Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, 1090, Vienna, Austria. Andreas.Kaiser@umweltbundesamt.at.

Rudolf Aro (R)

Man-Technology-Environment Research Centre (MTM), Örebro University, 701 82, Örebro, Sweden.

Anna Kärrman (A)

Man-Technology-Environment Research Centre (MTM), Örebro University, 701 82, Örebro, Sweden.

Stefan Weiss (S)

Environment Agency Austria, Spittelauer Lände 5, 1090, Vienna, Austria.

Christina Hartmann (C)

Environment Agency Austria, Spittelauer Lände 5, 1090, Vienna, Austria.

Maria Uhl (M)

Environment Agency Austria, Spittelauer Lände 5, 1090, Vienna, Austria.

Martin Forsthuber (M)

Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, 1090, Vienna, Austria.
Department of Environmental Health, Center for Public Health, Medical University of Vienna, 1090, Vienna, Austria.

Claudia Gundacker (C)

Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, 1090, Vienna, Austria.

Leo W Y Yeung (LWY)

Man-Technology-Environment Research Centre (MTM), Örebro University, 701 82, Örebro, Sweden. Leo.Yeung@oru.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH